Insight Molecular Diagnostics Inc. · NASDAQ:IMDX
Insight Molecular Diagnostics — Oncocyte — Investor Presentation (January 2024)
20 slides from Insight Molecular Diagnostics's investor presentation, Jan 24, 2024
Slide 1: Oncocyte Investor Presentation
Oncocyte Investor Presentation NASDAQ: OCX Josh Riggs CEO Q1 2024
Slide 2: Forward Looking Statement
Forward Looking Statement Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include, amo
Slide 3: Oncocyte Investor Summary
Oncocyte Investor Summary 3 novel precision - Differentiated, capital-light commercial model diagnostic tests focused on profitability, not just revenue for oncology - Competitive proprietary, patented technologies and transplant, and published clinical data representing a - Potential disruption of
Slide 4: Differentiated Strategy
Differentiated Strategy Focused on Profitability
Slide 5: Oncocyte Diagnostic Product Market Opportunity
Oncocyte Diagnostic Product Market Opportunity Three novel diagnostic tests addressing large reimbursed markets Transplant Oncology Is the transplanted organ Will patient benefit from Is the immunotherapy drug damaged? immunotherapy? working? $500M est. revenue currently $1.5B est. revenue generated
Slide 6: Differentiated, Capital-light Commercial Model
Differentiated, Capital-light Commercial Model Development and commercial model optimized for speed to market, product margin, and capital efficiency Development Commercial Service Lab Kitted Product • Clinical development • Strategic partner distributes product • Supports FDA pathway • Product targ
Slide 7: Diagnostic Development and Commercialization
Diagnostic Development and Commercialization Kitted products are packaged and distributable globally Traditional Model Oncocyte Approach Selling a central lab service to physicians Selling a high-margin kitted product to existing labs Large Small Sales Sales - Kitted product Force - No scale economi
Slide 8: Transplant Central Lab Service Example
Transplant Central Lab Service Example Transplant centers have volume and capability just missing the technology Highly Concentrated Market High Capability Labs <100 transplant centers in US market Most transplant centers are in academic generate approx. 80% of the volume1 settings with sophisticate
Slide 9: Oncocyte Going Forward
Oncocyte Going Forward $20 – 30M - Our service lab infrastructure remains lean, supporting reimbursement and clinical Anticipated breakeven development at modest revenue - Partners share costs of commercializing our distributable kitted product - High-margin, low-complexity business model based on p
Slide 10: Product Spotlight
Product Spotlight ONCOCYTE Where Tomorrow LIVES
Slide 11: For cause testing example
For cause testing example PROBLEM: SOLUTION: Current Standard All patients newly of Care performs Elevated Liver/Kidney transplanted and being Elevated Liver/Kidney biopsies on patients Function Tests monitored for rejection Function Tests that may not need one are eligible for VitaGraft leading to
Slide 12: Transplant - High Demand, Fast Growing Space
Transplant - High Demand, Fast Growing Space • Central service lab competitors currently generating $500M in annual revenue from kidney & heart transplant tests1 • Highly litigious market limits new market entrants • Labs without an IP position are limited, generating Planned VitaGraft demand to lic
Slide 13: Milestone Spotlight – Building Momentum in Transplant
Milestone Spotlight – Building Momentum in Transplant First coverage decision for our proprietary technology opens largest transplant market and is driving partnering conversations First test to report out data from an interventional study raising the bar for clinical validation and expands potentia
Slide 14: Late-stage cancer therapy is a $100B decision
+ Late-stage cancer therapy is a $100B decision that is only getting more complicated • Combines three elements of the tumor micro- • Blood test, uses common tumor biology, copy environment into one easy to interpret score number variation, to identify response to • Competitors currently generating
Slide 15: Next Steps
ONCOCYTE Where Tomorrow LIVES
Slide 16: Recent Accomplishments
Recent Accomplishments Slide Approx 50% reduction Coverage for VitaGraft Kidney in operating expense - $2B US Market Financial Highlights Manufacturing of Transplant - $19.1M on hand at end of Q2 RUO product started in Q2 - Runway well into 2024 - Projected quarterly burn Clinical Development below
Slide 17: 1H 2024 Major Milestone Opportunities
1H 2024 Major Milestone Opportunities Planned Milestones - - Manufacturing process validation complete - Announce global strategic partner for GraftAssure assay - Publish ESOT data in Kidney Transplant - Continue processing DetermaIO pivotal 862 patient study in triple negative breast cancer - Publi
Slide 18: Experienced Leadership Team
Experienced Leadership Team Pioneering Molecular Diagnostics JOSH RIGGS EKKEHARD SCHÜTZ, YUH-MIN (JOHNSON) President & Chief MD, PHD, FAACC CHIANG, PHD Executive Officer Chief Science Officer Chief Technology Officer 18 NASDAQ: OCX
Slide 19: Oncocyte Investor Summary
Oncocyte Investor Summary 3 novel precision - Differentiated, capital-light commercial model diagnostic tests focused on profitability, not just revenue for oncology - Competitive proprietary, patented technologies and transplant, and published clinical data representing a - Potential disruption of
Slide 20: Joshua Riggs, President & CEO
JOSHUA RIGGS, PRESIDENT & CEO JRIGGS@ONCOCYTE.COM